Pipeline

Our clinical program for relugolix combination tablet* consists of three international Phase 3 clinical trials, two in women with endometriosis-associated pain (SPIRIT 1 & 2) and one for the prevention of pregnancy (SERENE).

We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, as a potential trigger of egg maturation in women undergoing assisted reproduction, including in vitro fertilization (IVF).

*tablet is the intended commercial presentation based on pharmaco-equivalence data with relugolix combination therapy (co-administration of relugolix 40 mg with estradiol 1.0 mg and norethindrone acetate 0.5 mg)

Program

Phase 1

Phase 2

Phase 3

Filed

Approved

ORGOVYX® (relugolix)

For patients and healthcare providers in the United States, you can learn more about ORGOVYX® by visiting the product website and downloading the full U.S. Prescribing Information and Patient Information.

MYFEMBREE® (relugolix, estradiol, and norethindrone acetate)

For patients and healthcare providers in the United States, you can learn more about MYFEMBREE® by visiting the product website and downloading the full U.S. Prescribing Information including BOXED WARNING and Patient Information.

SPIRIT Study

A study evaluating relugolix combination tablet for the management of moderate to severe pain associated with endometriosis.

SERENE Study

A study evaluating relugolix combination tablet in women with endometriosis or uterine fibroids for the prevention of pregnancy.

MVT-602

A study evaluating MVT-602 in female infertility as part of assisted reproduction.

Learn more about our clinical trials

We cannot achieve our mission to redefine care for women and for men without clinical trials. All across the world, patients, families, physicians, and clinics support these trials as we strive to turn our purpose-driven science into empowering medicines.

View clinical trials